Cutting edge technology
Cutting edge technology
NexCalibur is developing technologies that enable:
Highest accuracy of neoantigen identification using multi-omics profiling, proprietary AI pipeline and fast ex vivo validation
Shortest overall vaccine production timeline (3 weeks) and lowest cost ($15,000 for whole treatment) advancing early and combinatorial treatment with highest efficacy
Applicable for both cancer treatment and cancer prevention